Matches in Nanopublications for { ?s ?p "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }
Showing items 1 to 7 of
7
with 100 items per page.
- NP548719.RAfED_JxH9isHq6_EsSqLgoeWuTvxIRIi_fmno21qJ4Qk130_assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP548719.RAfED_JxH9isHq6_EsSqLgoeWuTvxIRIi_fmno21qJ4Qk130_provenance.
- NP645364.RAcVB_IZnCiZpl_DRcVztOK5M6r9npcxcocFSQHUhsf-U130_assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP645364.RAcVB_IZnCiZpl_DRcVztOK5M6r9npcxcocFSQHUhsf-U130_provenance.
- NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP496443.RA5BTPY0v_79hIdO6pu1YsZJotyohqbIgV6StNwOFScp8130_provenance.
- NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP929012.RA_X6oNmcMkG7pMN2k6OPdAJTEKt6VfCTma7k_LxLZc5A130_provenance.
- assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
- assertion description "[We conducted an international, randomized, double-blind, placebo-controlled trial evaluating the safety and efficacy of an anti-interleukin-5 monoclonal antibody, mepolizumab, in patients with the hypereosinophilic syndrome.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.